Other
Granulocyte Colony Stimulating Factor
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Granulocyte Colony Stimulating Factor is an early-stage landscape with 0 programs across 2 companies. The most active players are Amgen, Shantha Biotechnics Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Completed5 · 56%
Unknown status3 · 33%
Recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial
Completed·—·Phase 1/2·NCT01441427·93 enrolled
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
Completed·—·N/A·NCT04971304·16,506 enrolled
The Effect of Granulocyte Colony Stimulating Factor Versus Human Chorionic Gonadotropin in Females With a History of RIF
Unknown status·—·N/A·NCT04604054·100 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)